Drug intelligence / Profile preview

B8572-ADC

Development stage: Preclinical
Lead developer: Nanolattix
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

B8572-ADC is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by Shanxi Naan Biotechnology. It is designed to target multiple antigens simultaneously, potentially enhancing tumor specificity and overcoming resistance mechanisms common in monovalent ADCs. The drug is currently being investigated for the treatment of various solid tumors, including lung cancer, gastric cancer, and breast cancer. It is administered via intravenous injection.

Beyond the preview

Go deeper on B8572-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B8572-ADC.

Explore the full profile